Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Misses Revenue Estimates
08:24am, Thursday, 11'th May 2023
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.14 per share a year ago.
Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
06:15am, Monday, 08'th May 2023
RESEARCH TRIANGLE PARK, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
Fennec Pharmaceuticals Gains Momentum With Industry Endorsements
08:43am, Wednesday, 05'th Apr 2023
Fennec Pharmaceuticals received FDA approval for Pedmark, a drug addressing cisplatin-induced ototoxicity in pediatric patients. The National Comprehensive Cancer Network (NCCN) and the European Medic
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Lags Revenue Estimates
08:22am, Thursday, 30'th Mar 2023
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -8.33% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
Why Earnings Season Could Be Great for Adherex Technologies (FENC)
01:44pm, Thursday, 23'rd Feb 2023 Zacks Investment Research
Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
11:00am, Tuesday, 31'st Jan 2023 GlobeNewswire Inc.
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~
US Stocks Open Lower; Dow Dips 250 Points
03:11pm, Wednesday, 25'th Jan 2023 Benzinga
U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Wednesday.
Following the market opening Wednesday, the Dow traded down 0.74% to 33,484.47 while the NASDAQ fell
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
12:19pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~
Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale
05:45am, Monday, 16'th Jan 2023
After two rejections, Fennec Pharmaceuticals finally secured FDA approval for its only asset, Pedmark. Additionally, the company secured non-dilutive capital to help initial commercialization effor
Expert Ratings for Fennec Pharmaceuticals
08:05pm, Tuesday, 22'nd Nov 2022 Benzinga
Within the last quarter, Fennec Pharmaceuticals (NASDAQ:FENC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
07:01pm, Tuesday, 22'nd Nov 2022 Benzinga
Within the last quarter, Fennec Pharmaceuticals (NASDAQ:FENC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
4 Analysts Have This to Say About Fennec Pharmaceuticals
05:02pm, Tuesday, 22'nd Nov 2022 Benzinga
Within the last quarter, Fennec Pharmaceuticals (NASDAQ:FENC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
Where Fennec Pharmaceuticals Stands With Analysts
03:04pm, Tuesday, 22'nd Nov 2022 Benzinga
Within the last quarter, Fennec Pharmaceuticals (NASDAQ:FENC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
0
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
12:10pm, Friday, 11'th Nov 2022 GlobeNewswire Inc.
~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Met
Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients
03:52am, Monday, 24'th Oct 2022
After two CRLs, PEDMARK has finally been approved for preventing chemo-induced hearing loss in pediatric cancer patients. In addition to being both safe and effective, PEDMARK has not shown itself to
